Gubra

We are looking forward to Anne-Marie Levy Rasmussen joining us soon at Gubra as our new Chief Operating Officer starting in February! Anne-Marie brings extensive global pharma experience and a proven track record in operational leadership and digital innovation from companies like GlaxoSmithKline and Bavarian Nordic. Her expertise in scaling, governance, and process optimization will undoubtedly play a key role in driving Gubra forward. Please join us in giving Anne-Marie a warm welcome. Read the full press release here: https://lnkd.in/dAf6H_Cm   #WelcomeToGubra

Gubra reports the most comprehensive phenotyping and pharmacological validation study to date in the CDAA-HFD mouse model of #MASH. We in-depth evaluated disease progression and responsiveness to dietary intervention and six clinically relevant drugs, including resmetirom, semaglutide, lanifibranor, elafibranor, obeticholic acid, and firsocostat. Read the paper in the American Journal of Physiology-Gastrointestinal and Liver Physiology to learn more about the model's applicability in preclinical drug development. Find the publication here: https://lnkd.in/dPDrtapa Learn more about Gubra's preclinical services in MASH here: https://lnkd.in/exij4MZg #PreclinicalResearch #MASHresearch #CDAAHFDModel #DrugDevelopment

Gubra’s drug discovery platform streaMLine enables machine learning-guided design and development of therapeutic peptide drugs. In this recent paper published in Scientific Reports, we demonstrate the applicability of streaMLine to optimize the PK and PD properties of lipidated CGRP antagonists. Read more about streaMLine here: https://lnkd.in/e_QUpZXw Download the publication here: https://lnkd.in/dkry5jnd #PeptideDrugDiscovery #MachineLearning #streaMLine

Are you wondering where to find us this January? This Monday, January 13th, we'll be at the J.P. Morgan Health Conference in San Francisco, where Line Holten Reimer and Lise Christine Biehl Rudkjær will be available to connect and share insights with you. Later this month, our VP, Michael Feigh, will attend the EASL SLD Summit in Estoril, Portugal, where he will present our most recent data using our GAN DIO-MASH model on a poster titled "Hepatoprotective effects of the oral fatty acid synthase inhibitor TVB-3664 in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH". You can download the poster here and join him for a discussion on our newest findings: https://lnkd.in/dQh9JcWH We look forward to meeting you! #SLDSummit #JPMorganHealthConference #ScientificResearch

We are thrilled to share the exciting news about a new partnership between Gubra and Boston based Amylyx Pharmaceuticals to develop a novel long-acting GLP-1 receptor antagonist.     “We are pleased to partner with Amylyx to advance GLP-1 receptor antagonism research. This collaboration and development agreement is an example of leading pharmaceutical companies partnering with us for our machine learning-based peptide drug discovery platform. This is yet another testimony that our streaMLine platform can be used to develop peptide drug candidates for a very broad range of diseases,” said Henrik Blou, CEO of Gubra.    Read the full press release here: https://lnkd.in/d97gV7KV Read more about our ML/AI-driven peptide drug discovery platform streaMLine here: https://lnkd.in/e_QUpZXw   #Collaboration #Biotech #DrugDiscovery #PeptideTherapeutics #GLP1ReceptorAntagonist 

Rapid weight loss can lead to muscle loss (sarcopenia), emphasizing the need for therapies that promote sustainable, muscle-preserving weight loss. Curious about how to benchmark your preclinical anti-obesity drug candidates for muscle-sparing effects? Explore our findings in the poster below and get in touch with us here: https://lnkd.in/daf3MB3f #ObesityResearch #MusclePreservation #ObesityDrugDevelopment #PreclinicalResearch

Choosing the right partner for #preclinical development is crucial for pharmaceutical and biotechnology companies. Gubra specializes in providing optimized, translational services that help streamline and accelerate your preclinical research. Let us help advance your science with our robust and reliable CRO services. Swipe through the carousel to discover why Gubra is the optimal choice for your preclinical needs and read more about our services here: https://lnkd.in/dUsHGtdD #PharmaceuticalResearch #Biotechnology #PreclinicalDevelopment #PreclinicalCRO

Gubra’s GAN DIO-MASH mouse model is an industry-leading, translational mouse model of liver biopsy-confirmed #MASH. We have rigorously validated the model using a series of clinically relevant anti-MASH drugs, including the glucagon-like peptide-1 (GLP-1) analogue semaglutide. Semaglutide has recently been reported to promote resolution of MASH and improve fibrosis stage in a recent pivotal clinical phase 3 trial in MASH patients (ESSENCE). Our studies indicate that histological outcomes of long-term semaglutide treatment in GAN DIO-MASH mice are comparable to corresponding topline results reported from the ESSENCE trial. Download the poster below and head to our website to learn more: https://lnkd.in/d_J4qN_E #TranslationalResearch #PreclinicalResearch #LiverHealth

Season's greetings from the entire team at Gubra! During this festive season, we extend our heartfelt thanks for your trust and collaboration. We are proud to support your preclinical research needs and look forward to achieving new milestones together in the year ahead. May your holidays be filled with joy, and may the New Year bring new opportunities and success. #TeamGubra #MilestonesAhead #PreclinicalResearch

We are happy to announce that, in close collaboration with Terns Pharmaceuticals, we have generated and validated a new humanized GLP-1 receptor mouse model, in which the endogenous murine GLP-1 receptor has been replaced by the human receptor at the whole-body level. This model is now available at Gubra for all our clients and will provide a physiologically relevant and translational platform to investigate in vivo efficacy, potency, and downstream signaling pathways of small-molecule GLP-1 receptor agonists. The easy accessibility of the model, as lean or obese (DIO), combined with Gubra's extensive expertise and capabilities in #obesity and metabolic diseases, will provide an excellent preclinical tool for anyone who wants to test a wide range of non-peptide GLP-1R agonists and translate their preclinical pharmacodynamics to the clinic. Check out our website or download the poster to learn more: https://lnkd.in/eCC4bcE3 #ObesityResearch #MetabolicResearch #NewMouseModel #PreclinicalResearch